Our Pipeline

We advance antibody science in areas with the greatest human impact.

Target PRODUCT Discovery ActRIIA/B - Human Metabolism Candidate Validation OB-24-02 POC Efficacy IND- Enabling STATUS Long Acting RSV OB-24-01 STATUS Rare Autoimmune OB-25-01 STATUS Undisclosed Oncology ADC OB-25-02 STATUS

PRODUCT Target: RSV
 Candidate
Validation Product: OB-24-01 POC
Efficacy IND-
Enabling STATUS Target: ActRIIA/B -Human Metabolism
 Product: OB-24-02 STATUS Target: Undisclosed – Orphan Drug Product: OB-25-01 STATUS Target: Undisclosed Oncology ADC
 Product: OB-25-02 STATUS

Committed to Patients: OCMS Bio’s Drive for Safer, Smarter Therapies

With a mission to improve patient health and quality of life, OCMS Bio’s pipeline is built to resolve issues with efficacy, safety and dose frequency and size that current therapies are plagued with. That is why the OCMS team is committed to bring the best possible drugs to the patient, as quickly as possible.